A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden

Michael Willis, Knut ??degaard, Ulf Persson, Johan Hedbrant, Dan Mellstr??m, Mats Hammar
  • Clinical Drug Investigation, January 2001, Springer Science + Business Media
  • DOI: 10.2165/00044011-200121020-00004

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Professor Mats L Hammar

In partnership with: